Browsing by Author "Carreiro Martins, P"
Now showing 1 - 2 of 2
Results Per Page
Sort Options
- Asthma and COPD "Overlap": a Treatable Trait or Common Several Treatable-Traits?Publication . Gaspar Marques, J; Lobato, M; Leiria Pinto, P; Neuparth, N; Carreiro Martins, PIn the last years, disease classification of chronic respiratory diseases (CRD) has been vivaciously discussed and new concepts have been introduced, namely asthma-chronic obstructive pulmonary disease (COPD) overlap (ACO). Controversially the GOLD consensus document of 2020 considered that we should no longer refer to ACO, as they constitute two different diseases that may share some common traits and clinical features. The treatable traits approach has numerous strengths that are applicable to several levels of health care. In this paper we review the application of the treatable traits to CRD and describe in detail the ones already identified in patients with asthma and COPD. Treatable traits in CRD can be divided in pulmonary, extra-pulmonary and behavior/lifestyle risk factors. Patients with both asthma and COPD patients have clearly recognized treatable traits in all these subtopics but it is notorious the severe and frequent exacerbations, the associated cardiovascular disease and the low health related quality of life and productivity of these patients.
- Clinical Standards for Diagnosis, Treatment and Prevention of Post-COVID-19 Lung DiseasePublication . Visca, D; Centis, R; Pontali, E; Zampogna, E; Russell, AM; Migliori, GB; Andrejak, C; Aro, M; Bayram, H; Berkani, K; Bruchfeld, J; Chakaya, JM; Chorostowska-Wynimko, J; Crestani, B; Dalcolmo, MP; D’Ambrosio, L; Dinh-Xuan, AT; Duong-Quy, S; Fernandes, C; García-García, JM; de Melo Kawassaki, A; Carrozzi, L; Martinez-Garcia, MA; Carreiro Martins, P; Mirsaeidi, M; Mohammad, Y; Naidoo, RN; Neuparth, N; Sese, L; Silva, DR; Solovic, I; Sooronbaev, TM; Spanevello, A; Sverzellati, N; Tanno, L; Tiberi, S; Vasankari, T; Vasarmidi, E; Vitacca, M; Annesi-Maesano, IBACKGROUND: The aim of these clinical standards is to provide guidance on 'best practice' care for the diagnosis, treatment and prevention of post-COVID-19 lung disease.METHODS: A panel of international experts representing scientific societies, associations and groups active in post-COVID-19 lung disease was identified; 45 completed a Delphi process. A 5-point Likert scale indicated level of agreement with the draft standards. The final version was approved by consensus (with 100% agreement).RESULTS: Four clinical standards were agreed for patients with a previous history of COVID-19: Standard 1, Patients with sequelae not explained by an alternative diagnosis should be evaluated for possible post-COVID-19 lung disease; Standard 2, Patients with lung function impairment, reduced exercise tolerance, reduced quality of life (QoL) or other relevant signs or ongoing symptoms ≥4 weeks after the onset of first symptoms should be evaluated for treatment and pulmonary rehabilitation (PR); Standard 3, The PR programme should be based on feasibility, effectiveness and cost-effectiveness criteria, organised according to local health services and tailored to an individual patient's needs; and Standard 4, Each patient undergoing and completing PR should be evaluated to determine its effectiveness and have access to a counselling/health education session.CONCLUSION: This is the first consensus-based set of clinical standards for the diagnosis, treatment and prevention of post-COVID-19 lung disease. Our aim is to improve patient care and QoL by guiding clinicians, programme managers and public health officers in planning and implementing a PR programme to manage post-COVID-19 lung disease.